# Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure

> **NCT02142075** · PHASE3 · COMPLETED · sponsor: **Poitiers University Hospital**

## Conditions studied

- Renal Failure
- Critical Care
- Gram Positive Bacteria

## Interventions

- **DRUG:** Daptomycin

## Key facts

- **NCT ID:** NCT02142075
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-09
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2016-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02142075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02142075, "Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02142075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*